Navigation Links
UMMS and CIW grant key RNAi rights to Oxford Biomedica
Date:1/7/2008

WORCESTER, MA, AND WASHINGTON, DCThe University of Massachusetts Medical School and the Carnegie Institution of Washington announced today that they have entered into licensing agreements with Oxford BioMedica (LSE: OXB), a gene therapy company, that grants the company rights to key RNA interference (RNAi) patent rights.

The technology was invented by Nobel-prize winning scientists Andrew Z. Fire, PhD, and Craig C. Mello, PhD, and their colleagues. The seminal patent claiming this technology was first granted in the United States by the United States Patent and Trademark Office in 2003. Additional patent rights have been issued in Australia and other US and foreign applications are pending.

This seminal patent covers a process by which ribonucleic acid (RNA), the cellular material responsible for the transmission of genetic information, can silence a targeted gene within a living cell. The process, called RNA interference (RNAi), can shut down disease-causing genes or direct researchers to pathways for effective drug development.

Under the terms of the license agreements, Oxford BioMedica obtains non-exclusive rights in accordance with the established licensing program of the Carnegie Institution and the University of Massachusetts Medical School, as well as certain exclusive rights for human gene therapy applications of RNA interference using lentiviral vectors. A lentiviral vector is based on a type of virus that infects dividing and nondividing cells and stores its genetic information on a single-strand of RNA instead of the more usual double-stranded DNA. In exchange, Oxford BioMedica will pay an upfront payment, annual maintenance fees, milestone payments, and royalties on sales. Further details were not disclosed.

James P. McNamara, PhD, Executive Director of the Office of Technology Management of the University of Massachusetts Medical School commented: As the Medical School looks toward the convergence of RNAi, gene therapy, and cellular therapy, including stem cells as medical treatments, the potential drug development opportunities presented by Oxfords lentiviral vector delivery technology is intriguing to us. We have structured these license agreements to help the company pursue novel applications of RNA interference based on their established broad IP in the lentiviral vector delivery space. Our hope is to see the further advancement of the RNAi field toward novel therapies in the public interest.

To date, the Carnegie Institution, acting upon behalf of itself and the University of Massachusetts Medical School under an interinstitutional agreement, has granted approximately 50 non-exclusive licenses to companies using this invention.

All rights granted under the licensing agreements with Oxford BioMedica are subject to the concurrent rights of the existing non-exclusive licensees. The Carnegie Institution and the University of Massachusetts Medical School further anticipate continuing to issue new licenses for research and other purposes in this promising field.

The University of Massachusetts Medical School and the Carnegie Institution of Washington have entered into these agreements to promote the fullest development of the patent rights with anticipated benefits to the general public.


'/>"/>

Contact: Alison Duffy
alison.duffy@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Related biology news :

1. Five young Hebrew University scientists win first competitive EU grants
2. Study shows immigrant children are at increased risk of lead poisoning
3. Manomet Center awarded major NFWF grant to foster shorebird conservation
4. UT Southwestern secures $5 million NIH grant for lupus research
5. Computational mathematical sciences receives NSF grant for undergraduate research
6. JDRF awards University of Copenhagen professor with grant to conduct innovative diabetes research
7. K-State specialist in tick-borne pathogens receives $1.8 million grant
8. EMBO Installation Grants help 9 scientists set up in Europe
9. NCI renewal grant to develop new cancer therapies
10. Liang receives NIH grant for biofilm research
11. CONRAD receives $28.5M Gates Foundation grant for HIV prevention research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2016)... CHICAGO , Jan. 11, 2016  higi, ... via nearly 10,000 retail locations, web and mobile, ... than $40 million from existing investors. ... will be devoted to further innovate higi,s health ... app and web portal – including expanding services ...
(Date:1/7/2016)... -- This BCC Research report studies the global as ... identifying newer markets and exploring the expansion of the ... Includes forecast from 2015 to 2020. Use ... the expansion of the present application market for various ... technology, determine its current market size, and estimate the ...
(Date:1/6/2016)... 2016  Varam Capital, a provider of micro-finance inclusion ... deliver advanced authentication solutions to their clients. Varam supplies ... A loan of a few thousand rupees may make ... ability to purchase livestock or equipment for a small ... for a local store. ...
Breaking Biology News(10 mins):
(Date:2/3/2016)... 2016  Discovery Laboratories, Inc. (NASDAQ: DSCO ... KL4 surfactant therapies for respiratory diseases, today announced ... inducement award as a component of employment compensation ... President and Chief Executive Officer.  The award was ... 1, 2016 and granted as an inducement material ...
(Date:2/3/2016)... Ascendis Pharma A/S (Nasdaq: ASND ), ... TransCon technology to address significant unmet medical needs, today ... Leerink Partners Global Healthcare Conference Location: , Waldorf ... 2016 Time:  , 11:55am EST www.ascendispharma.com ... An audio webcast of this event will be posted ...
(Date:2/3/2016)... , Feb. 3, 2016 New ... more than $1 million for researchers in ... on health-related research that demonstrates exciting potential.   ... of funding for the New Jersey Health Foundation Research ... members at these educational institutions— Princeton University, Rutgers ...
(Date:2/3/2016)... ... 2016 , ... ProMIS Neurosciences is currently in the process ... propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company plans to ... on from the first misfolded Amyloid beta target announced on Nov. 12, 2015, ...
Breaking Biology Technology: